Please know that our thoughts are with those affected by the COVID-19 outbreak. At this time, we are dedicated to support those individuals who may be unable to travel to Rotterdam, Netherlands from affected regions. If you are unable to travel or have concerns about obtaining your VISA, we are happy to announce the opportunity for remote presentations during your scheduled time slot if your paper is accepted.
Get Ready for IEEE SENSORS 2020!
Conference Starts in
Call For Papers
Topics for IEEE SENSORS 2020 include
- Sensor Phenomenology, Modeling and Evaluation
- Sensor Materials, Processing and Fabrication (including Printing)
- Chemical, Electrochemical and Gas Sensors
- Microfluidics and Biosensors
- Optical Sensors
- Physical Sensors - Temperature, Mechanical, Magnetic and Others
- Acoustic and Ultrasonic Sensors
- Sensor Packaging (including Flexible Materials)
- Sensor Networks (including IoT and related areas)
- Emerging Sensor Applications
- Sensor Systems: Signals, Processing and Interfaces
- Actuators and Sensor Power Systems
- Sensors in Industrial Practices (Only for industry i.e. first author from industry)
- Live Demonstration of Sensors and Sensing Technologies
Albert Theuwissen received the degree in electrical engineering and his PhD from the Catholic University of Leuven (Belgium) in 1977 and 1983 respectively. In 1983 he joined Philips Research Labs (the Netherlands) and in 2002 he started working for DALSA. His whole career he was involved in R&D of solid-state image sensors.
He issued several patents and he is author or coauthor of 240+ technical papers, including a textbook "SolidState Imaging with ChargeCoupled Devices". He acted as general chairman of the International Image Sensor Workshop in ’97, ’03, ‘09 and in ’15, and as International Technical Program Chair of the ISSCC2010.
In 2001, he became part-time professor at the Delft University of Technology, the Netherlands. He left DALSA in 2007, and founded Harvest Imaging. Since then he is fully focusing on training, teaching and consulting in the field of solid-state imaging technology.
In 2011 he received the Electronic Imaging of the Year Award and in 2017 he was elected as the President of the International Image Sensor Society.
An-Suei Yang, Ph.D.
1987 Ph.D. Chemistry, The Johns Hopkins University, Baltimore, MD.
1986 M. S. Chemistry, The Johns Hopkins University, Baltimore, MD.
1979 B. S. Chemistry, National Tsing Hua University, Taiwan.
Positions and employment
2018 - Division director of the Physical and Computational Genomics division, Genomics Research Center, Academia Sinica.
2010 - Research Fellow, Genomics Research Center, Academia Sinica.
2007 - 2016 Deputy Director, Genomics Research Center, Academia Sinica.
2004 - 2010 Associate Research Fellow, Genomics Research Center, Academia Sinica.
2000 - 2004 Assistant Professor, Department of Pharmacology and Columbia Genome Center, Columbia
Topic: developing anti-SARS-CoV-2 nucleocapsid protein antibodies with phage-displayed synthetic antibody libraries designed with computational methods
Abstract: The SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) outbreak in late-2019 in Wuhan China has led to global COVID-19 (coronavirus infectious disease 2019) pandemic, declared by the World Health Organization in March 11, 2020. During the outbreak of infectious diseases, tests to detect infected patients are urgently needed. RT-PCR-based detection of viral genetic materials and antibody IgG and IgM responding to the pathogen infection in human blood can be deployed quickly once the pathogen’s genome sequence become known, but the downsides of these tests limit the broad deployment of the PCR-based tests, or do not provide information on the real-time contagiousness of the pathogen infection in the antibody tests. A third kind of test based on lateral flow immunoassay (LFIA) on viral antigens could provide infection information for disease treatment and prevention without additional facility and instrumentation with turnaround times of 15-20 minutes – much like existing rapid influenza diagnostic tests, and is of particular value for infectious disease outbreak control in regions of insufficient resources. The key component of the LFIA for an antigen is the capture and detection antibody pair binding the target antigen with high affinity and specificity on two distinctively separate epitopes on the antigen. Because attaining suitable antibodies could be time-consuming and labor/cost-intensive, the LFIA devices are usually the most difficult to achieve rapidly among the three kinds of tests. Facing the challenge, we generated antibodies in IgG form that recognize both SARS-CoV-2 and the original SARS-CoV nucleocapsid (N) proteins. None of the IgGs bind the N protein of other human coronavirus strains. Our group accomplished antibody discoveries in 19 days, by working with our phage-displayed synthetic antibody libraries1, which had been designed with artificial intelligence models trained on antibody-antigen interactions2, constructed with chemically synthesized DNA, and expressed and then stored with phage display systems3. The antibody discovery processes were carried out in bacterial cultures, without need for animal facilities, thus mitigating time, material and environmental costs while enabling successful development of useful monoclonal antibodies. After completing the anti-N protein IgG development, our group completed a LFIA device prototype within one month. This work establishes a technological platform for rapidly developing LFIA devices in responding not only to the current COVID-19 pandemic but also in managing other infectious disease outbreaks in humans and animals. Indeed, we applied the technological platform to develop LFIA devices for avian influenza virus antigen in 2016 (manuscript submitted) and for African swine fever virus antigen in 2019 (manuscript in preparation). Developing solutions in responding to the challenges from the COVID-19 pandemic, we have demonstrated that the phage-displayed synthetic antibody libraries designed with computational methodologies could drive innovations in treating and preventing diseases.